What is the role of olaparib in the treatment of pancreatic cancer?

Updated: Oct 02, 2020
  • Author: Tomislav Dragovich, MD, PhD; Chief Editor: N Joseph Espat, MD, MS, FACS  more...
  • Print

In December 2019, olaparib gained FDA approval for adults with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Clinical trial results showed a statistically significant increase of progression-free survival in these patients compared with placebo (7.4 months vs 3.8 months; P = 0.004). [100]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!